2 Mar

Five developments to watch out for in biosimilar patent litigation

With the number of US patent disputes between biologics innovators and makers of biosimilars increasing, we highlight five issues that IP professionals should have on their radar, including the impact of cases involving Amgen, Genentech, AbbVie and Boehringer Ingelheim

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth